Related Experiment Videos
[Drug prescription after acute coronary syndrome]
1Service de cardiologie B CHU Rangueil 31054 Toulouse. puel.jacques@chu-toulouse.fr
Insights
Following acute coronary syndrome, treatment focuses on managing atherosclerosis and myocardial health. Prescriptions combine lifestyle changes with statins and aspirin for secondary prevention and patient adherence.
Area of Science:
- Cardiology
- Vascular Medicine
- Internal Medicine
Context:
- Acute coronary syndrome (ACS) affects 150,000-180,000 new patients annually in France.
- Treatment targets both the underlying atherosclerosis and the compromised myocardium post-event.
- Secondary prevention is initiated immediately following the acute phase.
Purpose:
- To outline the dual therapeutic targets in managing patients post-acute coronary syndrome.
- To describe the components of secondary prevention strategies.
- To emphasize the importance of patient education and adherence in long-term management.
Summary:
- Treatment for ACS addresses evolving atherosclerosis and myocardial damage.
- Prescriptions integrate lifestyle modifications, statins, and aspirin based on individual risk.
- This marks the start of essential secondary prevention and patient follow-up.
Impact:
- Optimizes secondary prevention strategies for cardiovascular disease.
- Improves patient outcomes through risk-stratified and personalized treatment plans.
- Enhances patient engagement and adherence to long-term management protocols.
Abstract:
Each year in France, 150,000 to 180,000 new patients are the subject of prescriptions following acute coronary syndrome with or without ST segment elevation. There are two targets of the treatment, 1) atherosclerosis, a diffuse, evolving trouble which, in this situation, is coming out of an unstable phase, and 2) the myocardium, which has often been revascularized and has suffered deterioration of its contractile and electrophysiological characteristics to a greater or lesser extent. Prescriptions, based on proven factors and always centred around hygiene and dietary advice and the use of a combination of statins and aspirin, are adapted to suit the atherosclerotic and myocardial risk assessed for the individual patient. The prescription starts off the secondary preventive phase. It marks the first stage of the follow up, which is inevitable though of variable duration, for a disease which may evolve. It is the first step in the accompaniment of an attentive, informed patient whose confidence has been restored and whom must now avoid falling into the double trap of not taking the treatment sufficiently seriously or of obsessively overreacting.